secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0001193125-23-173847
Event type: litigation
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio settles derivative litigation; court preliminarily approves governance reforms and $1.175M fee award
--------------------------------------------------------------------------------

- Court preliminarily approved settlement of derivative lawsuit alleging misleading statements on COVID-19 vaccine INO-4800.
- Settlement includes corporate governance reforms and $1,175,000 payment for plaintiffs' attorneys' fees, subject to court approval.
- Final settlement hearing scheduled for October 11, 2023.
- Defendants deny wrongdoing; settlement is without admission of liability.
- Governance reforms address internal controls and oversight deficiencies alleged in complaints.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312523173847/0001193125-23-173847-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312523173847/d455953d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-173847

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer